Because there's a very high probability that that's all the patients PV-10 will need to show a statistically significant improvement. In fact, Moffitt got a statistically significant result with less than 10 patients with PV-10.
I believe management is reluctant to give any positive opinions on what they believe could occur in the future for fear of being accused of putting a spin on anything. It seemed their conference call was toned down and addressed the facts only. They expounded little on the prospects of BTD, when they are pursuing that, and at the same time not taking anything for granted by aggressively moving forward with phase III. It does seem that this stock was way oversold.